DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma

Published:2024-02-05 Issue:4 Volume:47 Page:1129-1148
ISSN:2211-3428
Container-title:Cellular Oncology
language:en
Short-container-title:Cell Oncol.

Author:

Li Rui,Wen Xin,Lv Ru-xue,Ren Xian-yue,Cheng Bing-lin,Wang Yi-kai,Chen Ru-zhen,Hu Wen,Tang Xin-Ran

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13402-024-00917-x.pdf

Reference58 articles.

1. H. Sung, J. Ferlay, R.L. Siegel, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021)

2. K.D. Shield, J. Ferlay, A. Jemal, et al., The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J. Clin. 67(1), 51–64 (2017)

3. J.P. Pignon, A. le Maître, E. Maillard, J. Bourhis, MACH-NC Collaborative Group, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92(1), 4–14 (2009)

4. J. Bauml, T.Y. Seiwert, D.G. Pfister, et al., Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J. Clin. Oncol. 35(14), 1542–1549 (2017)

5. J.D. Schoenfeld, G.J. Hanna, V.Y. Jo, et al., Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 6(10), 1563–1570 (2020)